These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12645447)

  • 21. Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis.
    Shaygannejad V; Janghorbani M; Vaezi A; Haghighi S; Golabchi K; Heshmatipour M
    Neurol Res; 2013 Jul; 35(6):636-41. PubMed ID: 23582109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability.
    Charles PD; Gill CE; Taylor HM; Putman MS; Blair CR; Roberts AG; Ayers GD; Konrad PE
    Mov Disord; 2010 Mar; 25(4):466-73. PubMed ID: 20131401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis spasticity daily management: retrospective data from Europe.
    Berger T
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):3-7. PubMed ID: 23369053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations.
    Borg-Stein J; Pine ZM; Miller JR; Brin MF
    Am J Phys Med Rehabil; 1993 Dec; 72(6):364-8. PubMed ID: 8260129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and treatment of spasticity reported by multiple sclerosis patients.
    Rizzo MA; Hadjimichael OC; Preiningerova J; Vollmer TL
    Mult Scler; 2004 Oct; 10(5):589-95. PubMed ID: 15471378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Spasticity and botulinum toxin in 2003. An update].
    Fève A
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):265-70. PubMed ID: 12746701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The management of cerebral palsy: subjectivity and a conundrum.
    Bodensteiner JB
    J Child Neurol; 1996 Mar; 11(2):75-76. PubMed ID: 8881980
    [No Abstract]   [Full Text] [Related]  

  • 28. Dynamometer-based measure of spasticity confirms limited association between plantarflexor spasticity and walking function in persons with multiple sclerosis.
    Kremer TR; Van Dillen LR; Wagner JM
    J Rehabil Res Dev; 2014; 51(6):975-84. PubMed ID: 25356797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults.
    Borrini L; Bensmail D; Thiebaut JB; Hugeron C; Rech C; Jourdan C
    Arch Phys Med Rehabil; 2014 Jun; 95(6):1032-8. PubMed ID: 24407102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New approaches to managing spasticity in children with cerebral palsy.
    Im D; McDonald CM
    West J Med; 1997 Apr; 166(4):271. PubMed ID: 9168686
    [No Abstract]   [Full Text] [Related]  

  • 32. Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis.
    Tintoré M
    Neurodegener Dis Manag; 2015; 5(6 Suppl):15-7. PubMed ID: 26611266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of spasticity in children with cerebral palsy].
    Matthews DJ; Balaban B
    Acta Orthop Traumatol Turc; 2009; 43(2):81-6. PubMed ID: 19448346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of intrathecal baclofen (ITB) therapy in spacticity.
    Ucar T; Kazan S; Turgut U; Samanci NK
    Turk Neurosurg; 2011 Jan; 21(1):59-65. PubMed ID: 21294093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity.
    Guillaume D; Van Havenbergh A; Vloeberghs M; Vidal J; Roeste G
    Arch Phys Med Rehabil; 2005 Nov; 86(11):2165-71. PubMed ID: 16271565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Italian consensus on treatment of spasticity in multiple sclerosis.
    Comi G; Solari A; Leocani L; Centonze D; Otero-Romero S;
    Eur J Neurol; 2020 Mar; 27(3):445-453. PubMed ID: 31652369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Spasticity in children cerebral palsy: diagnosis and treatment strategies].
    Kurenkov AL; Batysheva TT; Vinogradov AV; Ziuziaeva EK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(7 Pt 2):24-8. PubMed ID: 23330188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution.
    Draulans N; Vermeersch K; Degraeuwe B; Meurrens T; Peers K; Nuttin B; Kiekens C
    Clin Rehabil; 2013 Dec; 27(12):1137-43. PubMed ID: 23858524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a 4-week period of unloaded leg cycling exercise on spasticity in multiple sclerosis.
    Sosnoff J; Motl RW; Snook EM; Wynn D
    NeuroRehabilitation; 2009; 24(4):327-31. PubMed ID: 19597270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.